Raymond James Financial Services Advisors’s Royalty Pharma RPRX Stock Holding History

Raymond James Financial Services Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$634K	Sell	22,408 -4	-0%	-$111	﹤0.01%	2459
2024 Q2	$591K	Buy	22,412 +2,363	+12%	+$65.5K	﹤0.01%	2410
2024 Q1	$609K	Buy	20,049 +118	+0.6%	+$3.48K	﹤0.01%	2375
2023 Q4	$560K	Hold	19,931	–	–	﹤0.01%	2337
2023 Q3	$541K	Sell	19,931 -500	-2%	-$14.8K	﹤0.01%	2277
2023 Q2	$628K	Buy	+20,431	New	+$692K	﹤0.01%	2210
2022 Q1	–	Sell	-5,194	Closed	-$207K	–	3450
2021 Q4	$207K	Buy	+5,194	New	+$202K	﹤0.01%	2959

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Raymond James Financial Services Advisors's RPRX Position: Q3 2024 in Review

Raymond James Financial Services Advisors reduced its Royalty Pharma (RPRX) stake by 0.02% in Q3 2024, selling an estimated $111 and leaving 22,408 shares worth $634K. The position accounts for ﹤0.01% of the portfolio, ranked #2459.

Raymond James Financial Services Advisors first reported a position in RPRX in Q4 2021 and has held it in 7 quarters since. 395 funds tracked by Wall St. Rank hold RPRX as of Q3 2024.

Raymond James Financial Services Advisors held 22,408 shares of Royalty Pharma worth $634K as of Q3 2024.
Raymond James Financial Services Advisors sold 4 Royalty Pharma shares in Q3 2024, an estimated $111.
Royalty Pharma made up ﹤0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #2459 holding.
Raymond James Financial Services Advisors first reported a position in Royalty Pharma in Q4 2021 and has held it in 7 quarters since.
395 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.